Private Market View

Malin Lanrui Biotechnology

Xiamen, China · Founded 2023 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include QS Capital.
  • Status: Privately Held (backing).

Investors

1
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Malin Lanrui Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Malin Lanrui Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Malin Lanrui Biotechnology

Operator of a marine-derived biotechnology compounds firm intended for applications in health, nutrition, and cosmetic formulations. The company offers to utilize extraction and purification technologies tailored to bioactive substances sourced from marine organisms, serving pharmaceutical, nutraceutical, and personal care markets to access stable, high-purity ingredients with consistent performance across diverse formulation environments, including temperature-sensitive and pH-variable conditions.

Sector
Healthcare
HQ
Xiamen, China
Founded
2023
Ownership
Privately Held (backing)
PA Mark — not yet priced

Malin Lanrui Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Malin Lanrui Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Malin Lanrui Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.